1160264-96-9

Basic information

• Product Name: 2-(3-chlorophenyl)-3-methylquinoline-4-carbonyl chloride
• Synonyms: 2-(3-chlorophenyl)-3-methylquinoline-4-carbonyl chloride;4-quinolinecarbonyl chloride, 2-(3-chlorophenyl)-3-methyl-
• CAS NO: 1160264-96-9
• Molecular Formula: C17H11Cl2NO
• Molecular Weight: 316.18134
• Mol File: 1160264-96-9.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(3-chlorophenyl)-3-methylquinoline-4-carbonyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-chlorophenyl)-3-methylquinoline-4-carbonyl chloride(1160264-96-9)
• EPA Substance Registry System: 2-(3-chlorophenyl)-3-methylquinoline-4-carbonyl chloride(1160264-96-9)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 1160264-96-9(Hazardous Substances Data)

Usage

Structure

A carbonyl chloride derivative of quinoline with a chlorine-substituted phenyl group

Usage

Serves as an intermediate in organic synthesis and pharmaceutical research for the synthesis of various pharmaceuticals, dyes, and other organic compounds

Reactivity

Reactive and potentially hazardous chemical

Handling

Should be handled with care

Upstream product

• 350997-46-5 2-(3-chlorophenyl)-3-methyl-4-quinolinecarboxylic acid 

Downstream Products

• 1336964-42-1 methyl 2-(3-chlorophenyl)-3-methyl-4-quinolinecarboxylate 

Relevant articles and documents

Discovery of GSK2193874: An Orally Active, Potent, and Selective Blocker of Transient Receptor Potential Vanilloid 4

Transient Receptor Potential Vanilloid 4 (TRPV4) is a member of the Transient Receptor Potential (TRP) superfamily of cation channels. TRPV4 is expressed in the vascular endothelium in the lung and regulates the integrity of the alveolar septal barrier. Increased pulmonary vascular pressure evokes TRPV4-dependent pulmonary edema, and therefore, inhibition of TRPV4 represents a novel approach for the treatment of pulmonary edema associated with conditions such as congestive heart failure. Herein we report the discovery of an orally active, potent, and selective TRPV4 blocker, 3-(1,4′-bipiperidin-1′-ylmethyl)-7-bromo-N-(1-phenylcyclopropyl)-2-[3-(trifluoromethyl)phenyl]-4-quinolinecarboxamide (GSK2193874, 28) after addressing an unexpected off-target cardiovascular liability observed from in vivo studies. GSK2193874 is a selective tool for elucidating TRPV4 biology both in vitro and in vivo.